Skip to main content
. Author manuscript; available in PMC: 2016 Jul 1.
Published in final edited form as: Leukemia. 2015 Feb 5;29(7):1530–1542. doi: 10.1038/leu.2015.20

Figure 5. TCR gene-engineered preTs confer long-term anti-leukemia protection in vivo by memory cell formation.

Figure 5

(A) Surviving mice of the co-transplantation experiments were re-challenged with 1.2 × 106 C1498-OVA leukemia three months after the first challenge. Non-transplanted mice were used as controls. Pooled data of two independent transplantations (n = 10) are shown. (B–D) 95 days after the second challenge, spleens of surviving animals were harvested (n = 4) and analyzed for the progenies of co-transplanted preTs. The expression of eGFP, Vα2, Vβ5 (B), and memory T-cell markers (C and D) was determined by flow cytometry. EM, effector memory; CM, central memory